<SEC-DOCUMENT>0001193125-25-263540.txt : 20251104
<SEC-HEADER>0001193125-25-263540.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104071025
ACCESSION NUMBER:		0001193125-25-263540
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20251104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kymera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001815442
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				812992166
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39460
		FILM NUMBER:		251446423

	BUSINESS ADDRESS:	
		STREET 1:		500 NORTH BEACON STREET, 4TH FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		857-285-5314

	MAIL ADDRESS:	
		STREET 1:		500 NORTH BEACON STREET, 4TH FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kymr-20251104.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-03T17:37:50.3471+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:kymr="http://www.kymeratx.com/20251104" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_aef45e2a-50cd-4f68-9bf7-abf7952e0f93" name="dei:EntityCentralIndexKey" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b">0001815442</ix:nonNumeric><ix:nonNumeric id="F_28af480e-a392-4669-82b9-9f85c68bceab" name="dei:AmendmentFlag" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="kymr-20251104.xsd"/></ix:references><ix:resources><xbrli:context id="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001815442</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-04</xbrli:startDate><xbrli:endDate>2025-11-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b1edc0c-7daf-4641-ae9d-c55b1a68e7b6" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0edf0e27-610e-47c8-ae23-28cd2615c8ce" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 4, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="font-size:12pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:22pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c07addc-002f-4410-8795-d7c4bdd47f79" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KYMERA THERAPEUTICS, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c537a833-31bd-45d6-8823-c3dfa293ae0e" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a3f01367-6d5e-492f-ba1e-817b06ece33b" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-39460</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aa0572d3-eb04-4dc0-9cef-fc4219ed78d8" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81-2992166</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of incorporation)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kymera Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c43e389-5088-4ea9-b324-4a1c7daf80f1" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">500 North Beacon Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bcd5fa23-a53a-479c-96cd-e0eeae18f502" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4th Floor</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e58ef04-7730-4c76-b0d0-60af5cfcdd8d" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c1f0bdf-d41d-4238-922a-86f6525fa887" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Massachusetts </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d22abd71-088f-43b1-8198-0f38053c0da0" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">02472</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Address of principal executive offices, including zip code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35db133c-9c79-435c-82c0-c2abe28d085e" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f12f646-c977-47f5-936f-94aea6acd63b" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">285-5300</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_b852d8b8-b166-485f-8937-4f12e0744f4c" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_6e4425d4-428e-46f4-9ec0-64c26a61a9bf" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_510d22af-e063-47c9-80cc-a91ebdf25d62" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_8a429b05-6020-4a08-b519-9be2da0988a1" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:40%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:40%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.021in;padding-left:0.021in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.021in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0.021in;padding-left:0.021in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.021in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Trade Symbol(s)</span></p></td>
     <td style="padding-top:0.021in;padding-left:0.021in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.021in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.021in;padding-left:0.021in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.021in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4944987b-aff5-4920-bb05-321248201262" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.021in;padding-left:0.021in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.021in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_04cdf130-c039-45f8-96c8-63edd4dd1001" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KYMR</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.021in;padding-left:0.021in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.021in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_449f45c0-f0d5-4781-bf2e-c36cabd5e357" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50110962-ddae-4295-95dd-758c85015a5b" contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02.	Results of Operations and Financial Condition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 4, 2025, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01.	Exhibits</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p>
   <table style="border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:14.28%;box-sizing:content-box;"/>
     <td style="width:2.82%;box-sizing:content-box;"/>
     <td style="width:82.9%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="kymr-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press release issued by Kymera Therapeutics, Inc. on November 4, 2025, furnished herewith.</span></a></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURE</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:47.54%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:3.9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:46.56%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kymera Therapeutics, Inc.</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: November 4, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Nello Mainolfi</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nello Mainolfi, Ph.D</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>kymr-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-11-03T17:37:50.4770+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.4in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img100385778_0.jpg" alt="img100385778_0.jpg" style="width:246px;height:57px;"></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Initiated KT-621 BROADEN2 Phase 2b trial in AD</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">KT-579 (IRF5) IND-enabling studies completed, with Phase 1 clinical trial expected to start in early 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Well-capitalized with $979 million in cash as of September 30, 2025, and runway into the second half of 2028</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Company to hold video conference call and webcast today at 8:30 a.m. ET</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Watertown, Mass. (November 4, 2025) &#x2013; </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Kymera Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the third quarter ended September 30, 2025, and provided business highlights and updates on its pipeline.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Our team has made impressive research, clinical, and regulatory progress this quarter to advance our first-in-class oral degrader medicines, and we look forward to several important milestones through the fourth quarter and early next year,&#x201d; said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. &#x201c;We&#x2019;ve completed patient enrollment and dosing in the KT-621 BroADen Phase 1b trial in AD, marking a significant moment in the industry as the first STAT6-directed agent in patients, and we plan to share the full data set next month. Additionally, we&#x2019;ve initiated the KT-621 BROADEN2 Phase 2b trial in AD and are on track to start BREADTH, the Phase 2b asthma study, in the first quarter of 2026, positioning us on an accelerated development path to multiple registrational studies across areas of significant unmet need.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Dr. Mainolfi continued, &#x201c;We were pleased to share additional preclinical efficacy data for KT-579 showcasing our novel oral approach to modulating IRF5, a key driver of multiple autoimmune disease pathologies. This program is on track for clinical entry in early 2026. These important milestones across our industry leading oral immunology pipeline underscore our focus on delivering groundbreaking medicines to patients around the world.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Business Highlights, Recent Developments and Upcoming Milestones</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">STAT6 Degrader Program</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In the Phase 1 clinical study in healthy volunteers, KT-621 demonstrated complete STAT6 degradation in blood and skin following low daily oral doses, reductions of multiple disease relevant Type 2 biomarkers, and a safety profile undifferentiated from placebo. KT-621, the first STAT6-directed drug to enter clinical evaluation, has the potential to transform treatment paradigms for more than 130 million patients around the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img100385778_0.jpg" alt="img100385778_0.jpg" style="width:246px;height:57px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">world, including children and adults, suffering from Type 2 diseases such as atopic dermatitis (AD), asthma, bullous pemphigoid (BP), chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), among others.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company has completed enrollment and dosing in the KT-621 BroADen Phase 1b trial, an open label study in patients with moderate to severe AD, with data expected to be reported in December 2025. This single arm study is evaluating two doses in approximately 20 patients with the objective to show that robust STAT6 degradation in blood and skin by KT-621 has a dupilumab-like effect on reducing multiple Type 2 biomarkers in the blood and on the Type 2 transcriptome of active AD skin lesions at four weeks. The trial will also assess effects on clinical endpoints such as Eczema Area and Severity Index (EASI) and Pruritus Numerical Rating Scale (NRS), among others.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The KT-621 BROADEN2 Phase 2b trial in AD has been initiated with topline data expected by mid-2027. This randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial is evaluating the efficacy, safety and tolerability of three doses of KT-621 in approximately 200 patients with moderate to severe AD over 16 weeks. Baseline eligibility criteria include an EASI score of at least 16, at least 10% of body surface area affected, and an average weekly Pruritis NRS score of at least 4. Patients from the study have the opportunity to participate in a 52-week open label extension period after completion of the trial. The primary endpoint is the percent change from baseline in EASI score at week 16. Secondary endpoints will evaluate a range of additional safety and efficacy measures, including the proportion of patients achieving EASI-50, EASI-75, a validated Investigator Global Assessment (vIGA) score of 0 to 1, and at least a 4-point improvement in Peak Pruritus NRS. More information on the BROADEN2 study can be found on clinicaltrials.gov (NCT# NCT07217015).</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company is on track to initiate BREADTH, a Phase 2b trial in moderate to severe asthma patients, in the first quarter of 2026. The parallel Phase 2b studies in AD and asthma are expected to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registrational studies across multiple Type 2 dermatology, gastroenterology and respiratory indications.</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In September, the Company presented results from the KT-621 Phase 1 healthy volunteer trial in late-breaking oral presentations at the European Academy of Dermatology and Venereology (EADV) and European Respiratory Society (ERS) Congresses. Additionally, the Company shared new preclinical data in a poster at EADV that builds upon KT-621&#x2019;s compelling characterization in disease-relevant contexts compared to dupilumab.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img100385778_0.jpg" alt="img100385778_0.jpg" style="width:246px;height:57px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IRF5 Degrader Program</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">KT-579 is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and master regulator of immunity. KT-579 has the potential to selectively block inflammation and restore immune regulation by inhibiting pro-inflammatory cytokines, Type I IFN, and autoantibody production while sparing normal cell function. In preclinical studies, KT-579 degraded IRF5 across multiple preclinical species and in all disease-relevant tissues. In preclinical models of lupus and rheumatoid arthritis (RA), KT-579 was equal or more efficacious than small molecule inhibitors and biologics currently marketed or in the clinic. In preclinical safety studies, KT-579 did not show any adverse effects of any type at all doses and concentrations tested. KT-579 has the potential to be the first novel mechanism with broad utility in diseases where effective and well tolerated oral therapies are needed, such as lupus, Sj&ouml;gren's, inflammatory bowel disease (IBD), RA and others.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Kymera has completed the KT-579 IND-enabling studies. The Company intends to advance KT-579 into Phase 1 testing in early 2026. </font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In October, the company presented two preclinical posters at the American College of Rheumatology (ACR) Annual Meeting. The new data shared demonstrated KT-579&#x2019;s activity in additional preclinical efficacy models of lupus and RA, further supporting IRF5 degradation as a first-in-class mechanism to address B cell activation as well as autoantibody and pro-inflammatory cytokine production in multiple autoimmune diseases.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Partnered Programs</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">KT-485/SAR447971, a selective, potent, oral IRAK4 degrader being advanced in partnership with Sanofi for immuno-inflammatory diseases, is in IND-enabling studies, with clinical entry expected in 2026. </font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Preclinical activities are ongoing under an exclusive option and license agreement with Gilead Sciences to advance the Company's CDK2 molecular glue program for the potential treatment of breast cancer and solid tumors. Upon exercise, which would result in an option exercise payment to Kymera, Gilead would assume all responsibility to develop, manufacture and commercialize all products resulting from the collaboration.</font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Corporate Updates</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In September, the Company appointed Brian Adams, JD, as Chief Legal Officer and Corporate Secretary to lead Kymera&#x2019;s legal, corporate governance, and intellectual property functions. </font></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Financial Results</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Collaboration Revenues:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Collaboration revenues were $2.8 million for the third quarter of 2025 compared to $3.7 million for the third quarter of 2024. Collaboration revenues recognized in the third quarter of 2025 were all attributable to the Company&#x2019;s collaboration with Gilead Sciences. Collaboration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img100385778_0.jpg" alt="img100385778_0.jpg" style="width:246px;height:57px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">revenues recognized in the third quarter of 2024 were all attributable to the Company&#x2019;s collaboration with Sanofi.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and Development Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Research and development expenses were $74.1 million for the third quarter of 2025 compared to $60.4 million for the third quarter of 2024. This increase was primarily due to increased expenses related to the investment in the Company&#x2019;s STAT6 program, platform and discovery programs, as well as costs related to continued growth in the research and development organization. Stock based compensation expenses included in R&amp;D were $8.4 million and $7.6 million for the third quarters of 2025 and 2024, respectively.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and Administrative Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> General and administrative expenses were $17.3 million for the third quarter of 2025 compared to $15.5 million for the third quarter of 2024. The increase was primarily due to an increase in legal and professional service fees in support of the Company&#x2019;s growth and an increase in personnel, facility, and other expenses. Stock based compensation expenses included in G&amp;A were $7.4 million and $7.3 million for the third quarters of 2025 and 2024, respectively.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net Loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss was $82.2 million for the third quarter of 2025 compared to $62.5 million for the third quarter of 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash runway into the second half of 2028, beyond multiple clinical inflection points in our pipeline.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Event Details</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Kymera will host a video conference call today, November 4, 2025, at 8:30 a.m. ET. To join the call please use </font><font style="color:#467886;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">this link</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">to register. A live webcast of the event will be available under </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">News and Events</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> in the Investors section of the Company&#x2019;s website at </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">https://www.kymeratx.com/</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. A replay of the webcast will be archived and available following the event for three months.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Kymera Therapeutics</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients&#x2019; lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston&#x2019;s top workplaces for the past several years. For more information about our science, pipeline and people, please visit </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.kymeratx.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> or follow us on </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">X</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">LinkedIn</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img100385778_0.jpg" alt="img100385778_0.jpg" style="width:246px;height:57px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">the  development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, including for the Phase 1b data readout of KT-621 in AD patients in December 2025, the initiation of Phase 2b studies of KT-621 in patients with AD and asthma in the fourth quarter of 2025 and first quarter of 2026, respectively, the effect of initial parallel development of Phase 2b studies in AD and asthma patients on acceleration of late parallel development across multiple indications, and the preliminary cross-study assessments comparing non-head-to-head clinical data of KT-621 to published data for dupilumab, the advancement of KT-579 into Phase 1 clinical testing in early 2026, the KT-485/SAR447971 program, objectives on the development of CDK2 degraders, and Kymera&#x2019;s financial condition and expected cash runway into the second half of 2028. The words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;estimate,&#34; &#34;seek,&#34; &#34;predict,&#34; &#34;future,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;target,&#34; &#x201c;upcoming&#x201d; and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that cross-trial comparisons may not be reliable as no head-to-head trials have been conducted comparing KT-621 to dupilumab, and Phase 1 clinical data for KT-621 may not be directly comparable to dupilumab&#x2019;s clinical data due to differences in molecule composition, trial protocols, dosing regimens, and patient populations and characteristics, that the results from the Phase 1b KT-621 trial may differ from the Phase 1a KT-621 data, that preclinical and clinical data, including the results from the Phase 1a trial of KT-621, is not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements, the ability of each party to perform its obligations under the Kymera and Gilead exclusive option and license agreement,  the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, whether Kymera will be able to fund development activities and achieve development goals, including those under the Kymera and Gilead collaboration, and other factors. These risks and uncertainties are described in greater detail in the section entitled &#34;Risk Factors&#34; in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img100385778_0.jpg" alt="img100385778_0.jpg" style="width:246px;height:57px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:58.623%;box-sizing:content-box;"></td>
     <td style="width:2.581%;box-sizing:content-box;"></td>
     <td style="width:17.907%;box-sizing:content-box;"></td>
     <td style="width:2.981%;box-sizing:content-box;"></td>
     <td style="width:17.907%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:15.95pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">KYMERA THERAPEUTICS, INC.</font></p></td>
    </tr>
    <tr style="height:15.95pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</font></p></td>
    </tr>
    <tr style="height:15.95pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</font></p></td>
    </tr>
    <tr style="height:15.95pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="5" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
    </tr>
    <tr style="height:3.15pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:22.35pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30,<br>2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br>2024</font></p></td>
    </tr>
    <tr style="height:11.95pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             978,737</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             850,903</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11.95pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;45,128</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;50,457</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets, operating lease</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;42,947</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;47,407</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11.95pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;35,232</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;29,268</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:2.96%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$          1,102,044</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             978,035</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$               37,236</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$               13,576</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11.95pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;80,303</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;84,017</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;38,247</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;44,823</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11.95pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:2.96%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;155,786</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;142,416</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:11.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:2.96%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;946,258</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;835,619</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:2.96%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities, preferred stock and stockholders&#x2019; equity</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$          1,102,044</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             978,035</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:31.66%;box-sizing:content-box;"></td>
     <td style="width:2.3%;box-sizing:content-box;"></td>
     <td style="width:13.98%;box-sizing:content-box;"></td>
     <td style="width:2.3%;box-sizing:content-box;"></td>
     <td style="width:13.98%;box-sizing:content-box;"></td>
     <td style="width:2.72%;box-sizing:content-box;"></td>
     <td style="width:13.98%;box-sizing:content-box;"></td>
     <td style="width:2.3%;box-sizing:content-box;"></td>
     <td style="width:16.78%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">KYMERA THERAPEUTICS, INC.</font></p></td>
    </tr>
    <tr style="height:15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</font></p></td>
    </tr>
    <tr style="height:15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</font></p></td>
    </tr>
    <tr style="height:15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="9" style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
    </tr>
    <tr style="height:3pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:23.45pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Three Months Ended <br>September 30,</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">Nine Months Ended<br>September 30,</font></p></td>
    </tr>
    <tr style="height:11.25pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration Revenue</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             2,764</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             3,741</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$           36,341</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$           39,678</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$           74,094</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$           60,410</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$         232,737</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$         168,431</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;17,336</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;15,455</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;51,252</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;47,202</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of long-lived assets</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3,855</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#x2014;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;3,855</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;4,925</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;95,285</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;75,865</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;287,844</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;220,558</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(92,521)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(72,124)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(251,503)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(180,880)</font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:2.96%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;10,444</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;9,697</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;27,413</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;27,964</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.75pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:2.96%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other expense</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(98)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(60)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(280)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(190)</font></p></td>
    </tr>
    <tr style="height:12.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:5.92%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;10,346</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;9,637</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;27,133</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;27,774</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:13.5pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$         (82,175)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$         (62,487)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$       (224,370)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$       (153,106)</font></p></td>
    </tr>
    <tr style="height:24pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             (0.94)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             (0.82)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             (2.71)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$             (2.09)</font></p></td>
    </tr>
    <tr style="height:14.25pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common stocks outstanding, basic and diluted</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;87,300,286</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;76,125,975</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;82,653,142</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;73,330,338</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.4in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img100385778_0.jpg" alt="img100385778_0.jpg" style="width:246px;height:57px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Investor and Media Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Justine Koenigsberg</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Vice President, Investor Relations</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">investors@kymeratx.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">media@kymeratx.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">857-285-5300</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img100385778_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img100385778_0.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $P!2$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^5?\ :;_Y
M.2_:$_[+A\6/_4]U^I/V7_C'>_L\?M)? 'X]:>TZW7P9^,WPS^*"I;[C)<P^
M!O&6C>)+JQ:-7C^T0:A:Z=-8W5H["*\MKB:UG#0S.IC_ &F_^3DOVA/^RX?%
MC_U/=?KP^OWJ$(U,/&$E>,Z,827>,H)-?--H_E^<Y4L5.K!VG3Q$IP?:4*CE
M%_)I,_W!;"^LM4L;+4].NH+[3]1M+>^L+VUE2:VO+*[A2XM;JWFC+)+!<021
MRPRH2DD;JZD@@U;K\V/^"//QR;]HO_@F)^Q3\4;B];4=5F^!GACP)XBU"20R
M7%_XJ^$#W?PC\4ZA>$JF+S4?$'@?4;^Z"HD?G7+F!?(,9/Z3U^%8BC+#UZU"
M?Q4*M2C+I[U.<H/3IK%G],X6O'%8;#XF'P8BA1KPZ^[6IQJ1U])(****R-PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRS*<0Z-3#RYL;B:3BY>TMIA8-II<E^:NUKS\M.\>2I&7]4W_ !%Z_P#!2?\
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M_P#C)^S-\:;7X<^ _#7PSU;1)_!.A>)'NO%VC>*;_51?:GJ&MVEQ$L^C>,]
MM!:)'IL#0QFQ,RN\I>>1618_CC_A\+^TQ_T(WP+_ /"9\?\ _P \VL+_ (*W
M?\G3Z?\ ]DH\(_\ IY\5U^8%?XK>.WT@?&?AOQA\1<AR+Q$XARS)\JXHS'!Y
M=E^&K4(X?"86E.*IT:2EAY24(+1)R;WUU/\ 3[PG\'O#+._#?@S-LUX,R;'9
MEF&0X+$XW&5Z55UL17J0O.K4<:T4Y2:ULDO+5GZN?\/A?VF/^A&^!?\ X3/C
M_P#^>;7TO^R5_P %/OB#\7_C9X8^%_Q;\+_#G1=(\:O<:/H>M^$;3Q'H]Q9>
M)6MYKC2;6^77?$_B2"^M]:N(%T:VAMTL9TU*^LW\Z6/?"?P,K2T;5]2\/ZQI
M6OZ-=S6&KZ)J5CJ^E7]NQ2>RU+3;J*]L;N!QRLUM=0Q31L.5=%/:O@^&/I7^
M-V3<1Y'FN:\?9_GF5Y?FN!Q69Y-C*F%J8;-,NI8BG+'8"JI8=<JQ>%56A&K&
M4*E&<XUJ<X5(1FOK,]^CYX6YGDN:Y?@.$<HRO'XS 8K#X',L-#$0KX#&5*,H
MX7&4VJ[N\/7]G5<)*4*L8RIU(RA.47_<=17D_P "_BGIOQK^$/P_^*.E^4D/
MC#PY9:C>6L3%TT[6X@UEX@TD.<%SI.NVNHZ<7('F?9?, VN*]8K_ '6RK,\#
MG65Y=G.68B&*RW-L!@\SR_%4]:>)P6/P]/%86O#^Y6H5:=2/E)'^4&/P.*RO
M'XW+,=1EA\;E^+Q.!QF'FK3H8K"5IT,11FOYJ=6G.$O.+"BBBN\Y HHHH **
M** "BBB@ HHHH **** /SK_;X_;8UC]E.P\$:)X$T;PSXA\?>,9-0U*2#Q2F
MJ76DZ+X9TMH;9KRYT_2-2T6]N+G5[^X>UTQUU6"&(:9J;S13E8DK\S_^'PO[
M3'_0C? O_P )GQ__ //-KY1_;8^-/_"]_P!H_P"(/C"SNOM7AO2[_P#X0WP:
MROO@/ACPO)-86MW:G<Q%OK=^=2\1*I(*OK#KM3&Q?E&O\3_&GZ5WBAF7B=Q;
M+@3CO-LDX0P.:5<IR#!Y7/#0PM;!97;!/,E*6'G4K/-L11KYE&=6<IQI8JG0
M7+3I0A'_ %#\,?H^\!X'@7AV/%G">79IQ'BL!3S#-\3CX5Y8BGBL?_M2P+BJ
MT84UE]&I2P3A"*C*I0J57S3JSE+]7/\ A\+^TQ_T(WP+_P#"9\?_ /SS:[;X
M9_\ !6#]HGQG\1_A_P"#]4\&?!:#3/%?C;PIX;U&>P\.^.8KZ&QUW7;#2[N6
MREN/B-=6\=W';W4CVTD]K<PI,J-+!,@:-OQMKU?X#?\ )<O@S_V5?X=_^I?H
M]?#<._25\=\5Q!D6%Q'B=Q-5P^)SC+,/7I3KX?EJT:V-H4ZM.5L,GRSA)QE9
MIV;UU/J\Y\$/";#Y1FM>CP+D=.M0RW'5:52-*MS0J4L+5G3G&]=ZQE%25[ZK
M7=G]I-%%%?[TG^2(4444 %%%% !1110 4444 %<3\3/$E]X,^''Q \8:7%:3
MZGX4\$^*_$FG07\<TMC-?:%H5_JEI%>Q6\]K<26DEQ:QI<QP75M,\+.L4\+E
M9%[:O*/CS_R0WXS?]DH^(G_J(:Q7C\0UZV%R#/,3AZDJ6(P^3YG7H58:3IUJ
M."KU*52+=TI0G&,HZ;I'IY+1I8C.,IP]:"J4:^9X"C5IR^&I2JXJE"I"5K.T
MH2<79K1GX)?\/A?VF/\ H1O@7_X3/C__ .>;1_P^%_:8_P"A&^!?_A,^/_\
MYYM?E'17^"O_ !,YX^_]'2XH_P#!^&_^9O+\^[/];?\ B!7A%_T060_^":__
M ,O\OS[L_5S_ (?"_M,?]"-\"_\ PF?'_P#\\VC_ (?"_M,?]"-\"_\ PF?'
M_P#\\VORCHH_XF<\??\ HZ7%'_@_#?\ S-Y?GW8?\0*\(O\ H@LA_P#!-?\
M^7^7Y]V?JY_P^%_:8_Z$;X%_^$SX_P#_ )YM'_#X7]IC_H1O@7_X3/C_ /\
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M_P )GQ__ //-K\HZ*/\ B9SQ]_Z.EQ1_X/PW_P S>7Y]V'_$"O"+_H@LA_\
M!-?_ .7^7Y]V?JY_P^%_:8_Z$;X%_P#A,^/_ /YYM'_#X7]IC_H1O@7_ .$S
MX_\ _GFU^4=%'_$SGC[_ -'2XH_\'X;_ .9O+\^[#_B!7A%_T060_P#@FO\
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M .>;7Y1T5/\ Q,YX^_\ 1TN*/_!^&_\ F;R_/NQ_\0*\(O\ H@LA_P#!-?\
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M?4/"$MR)-7T(3,V9KGP[J-X+NQB8M,VC:A)! BV6@ML_9:O^A;PD\2<I\6>
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MX:_"N6P\1^(5N8/,L=>U\3&7PSX5<2 PSPW5W;OJNL6[QS02Z/IEQI]TL?\
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M9A4DW>=;'U=$HZRT445_:A_, 4444 %%%% !1110 4444 %?'7[>/QJ'P/\
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M (<Y? W_ **?\5_^_GA#_P"9JOUYHH_XE7^C[_T;#(?_  ?FW_SQ\OS[L/\
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M !1110 4444 %%%% !1110 4444 -=E16=V5$12SNY"JJJ"69F) 55 )))
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MJ_P&_P"2Y?!G_LJ_P[_]2_1Z\HKU?X#?\ER^#/\ V5?X=_\ J7Z/7\[<*_\
M)3\.?]C[)_\ U88<_9\__P"1%G7_ &*<Q_\ 4.L?VDT445_TM'^'H4444 %%
M%% !1110 4444 %>4?'G_DAOQF_[)1\1/_40UBO5Z\H^//\ R0WXS?\ 9*/B
M)_ZB&L5X7%'_ "3/$7_8BS?_ -5^(/7X?_Y'V2?]C?+?_4VB?Q;4445_S2'^
MX)_6K_P3X_Y,X^!W_8"U[_U,_$E?9=?&G_!/C_DSCX'?]@+7O_4S\25]EU_T
M9^#_ /R:7PN_[-UP3_ZS66'^+?B1_P G$X]_[+3BG_U>8X****_13XL****
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M/I(_\GX\5?\ LL<U_P#3D3_8?P3_ .33< ?]DUE__I#/T_\ ^"2/_)T^H?\
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MOL]VJ^(!:L=)^&_A_4XTWS^#?AW;W5SIUC*LKPZWX@N_$?BE%MH=;MM.T_\
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M36I8Z=&=Z&:<7.,J&85FT[5*>24Y3RC#MQ3ABWF\X2J4:]&2_P!*OHM>&/\
MJIPK+C+-</R9]Q=0IU,)&I&U7 <.\T:N#I*ZO">:34,QKV;4L.LNC*,*M&HF
M5]I?L)?LTR_M)_&[3-,U:UDD^'?@G[)XJ^(,Y#"&ZTZ"Y TSPQYH&!/XIOHF
MLY$62*==&M];O+:19[),_&MI:75_=VMA8V\UY>WMQ#:6=I;1/-<75U<R+#;V
M]O#&&DEFGE=(HHD5GDD944%B!7];W[%'[-]K^S3\$=$\+WD$!\=>(S'XH^(=
M]'LD+^(;ZWB5-&AG4$OI_ANR6'2;8*[037<6HZI"D3:G,E? ?1-\%GXN^).'
MK9MA?;<&<'/#9UQ)[2'-0Q]559/*<ADWI+^U,31G4Q4'I+*\'CX*4*LZ+?V'
MTA?$Y>'7!%>EE^(5/B;B15\KR10E:MA*;A%9CFT5NOJ%"K&%":^''XG"2<90
MC42^MHHHH(HX((XX888TBAAB18XHHHU"1QQQH B1H@"HB@*J@*H  %2445_N
MFDDDDDDDDDE9)+1)):));(_RB;;;;;;;NV]6V]VWU;"BBBF(**** "BBB@ H
MHHH **** /YGO^"MW_)T^G_]DH\(_P#IY\5U^8%?I_\ \%;O^3I]/_[)1X1_
M]//BNOS K_GT^DC_ ,GX\5?^RQS7_P!.1/\ 8?P3_P"33< ?]DUE_P#Z0S]/
M_P#@DC_R=/J'_9*/%W_IY\*5_3#7\SW_  21_P"3I]0_[)1XN_\ 3SX4K^F&
MO]._H&_\F(C_ -EEQ%_Z:RP_A/Z6G_)V9?\ 9-9-_P"EXX_%;_@L%\%QJ?A?
MX?\ QXTJU#7GAJ\/@#Q;)%%NE?0=8DN=3\,WL\@QY=KI6MC5-/.XNTESXGM5
M4*J.3^!%?VG_ !K^&6F?&;X3>/\ X7ZMY2VWC/PUJ&DP7$P+)I^JE!<Z'JN
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MOB*8SZYXQ\1:OXDU1]S,BWFL7T]]+# &),=K;&;[/:0KB.WM8H8(E2.-%'\
M_3\\1_["X"R3PZP-?EQ_&V/^OYM"$O?AP]D-6C7C2J)-2@L?G,L#*C*[C4IY
M9C:3BTW;^OOHA<%?VMQ=FO&F+H\V$X7PGU3+Y2C[LLYS:G4I2J0;NI/"99'%
M1J1WA/'8:HFFE?DZ^_?^";/P8'Q;_:;\,ZCJ-F;GPS\+86^(FLM(C&W?4=)G
MAA\)V;28\LS2>)+BPU);9]WVJQTC45V-&DI7X"K^FC_@E9\%S\.?V>I/'^IV
MGD>(OC'JW_"0;I(U2>/PCHOVG3/"EO(=NYH[EY-:U^V;S"CVFNVQ"(X?=_#/
MT3?#C_B(_C5PUA\50]MDO"\WQ?G?-#FI2P^2U:,\OPM52]R<,;G-7+L-6HR=
MZF$GBI*,HTYH_JSZ0O&O^I7AAGE>A6]EFF>Q7#F5<LN6HJV9PJ1QE>FU[T)8
M7+*>-KTZL5[F(C03<7.+/TXK\H_^"PO_ ";/X&_[+IX9_P#4 ^)M?JY7Y1_\
M%A?^39_ W_9=/#/_ *@'Q-K_ %M^D[_R8+Q2_P"R8K_^I6%/\[? O_D[O /_
M &/J/_IFN?S=UZO\!O\ DN7P9_[*O\.__4OT>O**]7^ W_)<O@S_ -E7^'?_
M *E^CU_@YPK_ ,E/PY_V/LG_ /5AAS_6K/\ _D19U_V*<Q_]0ZQ_:31117_2
MT?X>A1110 4444 %%%% !1110 5Y1\>?^2&_&;_LE'Q$_P#40UBO5Z\H^//_
M "0WXS?]DH^(G_J(:Q7A<4?\DSQ%_P!B+-__ %7X@]?A_P#Y'V2?]C?+?_4V
MB?Q;4445_P TA_N"?UJ_\$^/^3./@=_V M>_]3/Q)7V77XT?LA?M]?LR?"3]
MG#X7?#KQQXRU?3?%?AC2M5M=8L;?P?XHU*&WFNO$NM:E"L=[8:7/:7 :TO;>
M0M#*ZJSE&(=64?27_#T#]CC_ **!KO\ X0/C/_Y35_O)X6^-G@]EGACX<Y=F
M/BAP#@<PR_@3A#!8[!8KBO)*&*P>,PO#^7T,3A<30J8V-2CB,/6ISI5J52,9
MTZD)0G%231_DMQ]X7>)&.X[XUQN#X#XNQ6#QG%O$>*PF*P_#^:5L/B<-B,XQ
ME6A7H588:4*M&M2G"I3J0DX3A)2BVG<_06BOSZ_X>@?L<?\ 10-=_P#"!\9_
M_*:C_AZ!^QQ_T4#7?_"!\9__ "FK[O\ XCSX)?\ 1VO#K_Q,,A_^;CY/_B$G
MBC_T;SC3_P 1O-O_ )E\_P ^S/T%HK\^O^'H'[''_10-=_\ "!\9_P#RFH_X
M>@?L<?\ 10-=_P#"!\9__*:C_B//@E_T=KPZ_P#$PR'_ .;@_P"(2>*/_1O.
M-/\ Q&\V_P#F7S_/LS]!:*_/K_AZ!^QQ_P!% UW_ ,('QG_\IJ/^'H'[''_1
M0-=_\('QG_\ *:C_ (CSX)?]':\.O_$PR'_YN#_B$GBC_P!&\XT_\1O-O_F7
MS_/LS]!:*_/K_AZ!^QQ_T4#7?_"!\9__ "FH_P"'H'[''_10-=_\('QG_P#*
M:C_B//@E_P!':\.O_$PR'_YN#_B$GBC_ -&\XT_\1O-O_F7S_/LS]!:*^0_A
M+^W-^SA\;O'&F_#KX=>+M5U;Q7JUOJ-U8V-UX3\2Z5#)#I5C/J5ZS7NI:;;6
MD9CM+:615DE5I&4(@9V /UY7W/#?%G#'&. J9KPGQ!DW$N64L54P53,,CS'"
M9I@Z>,HTZ-:KA9XC!U:U*.(ITL10J3I.2G&%:G)Q2G%OY3.^'L]X:Q<,OXAR
M?,\DQU2A#%0P>:X+$8#$SPU2=2G3KQHXFG3J2HSJ4:L(U%'E<Z52*=X22***
M*^@/'"BBB@ HHHH **** "BBB@ K^=C_ (+&_P#)<OAA_P!DHC_]2_Q+7]$]
M?SL?\%C?^2Y?##_LE$?_ *E_B6OY$^G#_P H^Y__ -CWA?\ ]6]$_HWZ*W_)
MX<J_[%&>_P#J!,_(:OTB_P""5'_)V^C_ /8B^-O_ $BMJ_-VOTB_X)4?\G;Z
M/_V(OC;_ -(K:O\ *7Z/7_)\O"?_ ++OAW_U8T3_ $!\9/\ DU7B#_V2>=?^
MH=4_I^HHHK_H5/\ '$**** "BBB@ HHHH **** .<\8Z['X7\(^*O$TSB.'P
M[X<US799"$8)'I&F76H.Y61XXV"K;EB))(T(&&=5RP_B"K^K#_@H[\7K+X5?
MLM^.;!;N*/Q#\3[=OAOH%F6S)<P>((VC\53&-2)!;VOA-=81[C'DQWMUIUO*
M<W<:O_*?7^2G[0[BC"9AQOP)PGAZT*N(X9X?S/,\=&$E+ZM7XFQ>#A2P]5+X
M*[PN14,4X2M+V&)P]2W+4BW_ *'_ $-LAQ&#X5XLXAK4Y4Z.>9Q@<#A92BX^
MWI9'A\3*I6IMKWZ2Q&;5J"DFX^VH5H?%"05_6-_P3FL)M._8P^"=O/@O)8^,
M[]<!E'DZK\1_&.IV_#JIR+>\B!(!5CED9D*L?Y.:_LY_9S\%S?#KX"?!WP3=
MPM!J'AWX<>$;'5H6QF/6SHMI/K:@;4(7^UYKTHK#>JD*[.X9VY_V>&4UJWB1
MQSGL82>'RW@B&4U9V?+&MG6?99C*$&]E*<,@Q+BGJU3G;1,V^F7F-*EP5PIE
M+DE6QO%,LQIQNN9TLKRG'8:M)+=J,\WH*36B<XWW1[/1117^N9_G4%%%% !1
M110 4444 %%%% !1110!1U/4K'1M-U#6-4NHK+3-*L;O4M1O)B1#:6-C!)=7
M=U,0"1%;V\4DLA )"(2 3Q7\7WQM^)=]\8OBW\0_B=J FCE\:>*M5UFUMIY/
M-DL-)DN&AT/2C)_&NDZ-#8:9&W0QVB8 '%?TJ?\ !2GXN_\ "K/V6_%MA9W!
MAU[XH7%O\-M)$<A65;/6X;BY\43,B#>UNWA:PU;3G?='''<ZG9AW8R)#-_*U
M7^4G[0KC[Z[Q%P=X;X.OS4,CP-;B?.:<'>+S+-7/!951K+[-?!9=A\7B(I+6
MCG,6V[I1_P! _H<\(_5<EXEXVQ-*U;-<73R'+)R5I+ Y>HXK,*E)_:I8K&UL
M/1DWM5RR225GS%?MQ_P1S^$_VK6_BE\;+^V#1:39V?PX\-3NI93?ZDUKX@\5
M.F1LCN+.QM_#,*2+NE-OJ]W%F.-V$WXCU_7K^Q-\)5^#'[,_PO\ "D]J+77-
M1T.+QCXI#*RW!\0^+@-;NK>[!P/M&D6MS9: VP!/+TF/!D.99/R[Z#? 7^MG
MC-1XAQ-%5,LX!RO$Y[4<X\U*6;XR,LKR6C+1VJPGB,7FE!W5JF57N[<K^]^E
M7Q=_J]X9U,FH57#'<7X^AE4%&7+4CEV&<<?F=5:ZTY1HX? 5EK>&86M9MKZK
MHHHK_:P_R_"BBB@"EJ6G6.L:=?Z3J=K#?:;JEE=:=J%E<+O@N[&]@DMKNUG3
MC?#<6\LD4BY^9'8=Z_B_^-_PUO/@]\7?B+\,KT3%O!OBS5M'M)YU*27ND1W#
M3:%J94\A=5T6;3]2C]8[I3SG-?VFU_.Y_P %??A./#WQ:\#_ !<L+8)8_$;P
MW)H6MRQJ3N\3^"S!!'<W+XVH]]X;U'1[.U0G+IH5RP^XV/X0^GWP'_;_ (7Y
M1QOA:'/CN!<ZA'%U(Q]Z.0\1RH9?BN9Q7-+V>;TLDE%2O&G3GB)IQYI7_K/Z
M(G%O]D<>9CPM7J\N%XKRN<L/3;]UYMDJJXS#V3TCSY=/-%)JSG.%&+YK1M^0
M5?M3_P $>/BZ=.\5_$GX(ZC<!;7Q)IT'Q \,QR2A$76=$-OI'B.U@C(S-=:I
MI%UI-X0&'EVOAJX?# DI^*U>W?LW?%:;X(_'/X:?$Y'D6T\,^)K1];2(G?/X
M:U-9-'\3VR *^9)] U#48X<H^V<QN%+(*_S1\">/7X:>+/!'%U2LZ&7X+.:.
M$SJ5WR?V%FJEEF<2G':I[# XNMBZ4)*WUC#T9IQE",X_W#XL<(KCCP\XIX<A
M257&8K+:N(RN-O>_M;+W''Y;&,M'#VN+P]+#U)+_ )<UJD6I1E*+_LRHJ.&:
M&YABN+>6*>WGBCF@GAD66&:&50\4L4J%DDBD1E>.1&975@RD@@U)7_0XFFDT
MTTTFFG=-/5--:--:IK<_QL::;3333:::LTUHTT]4T]T%%%%,04444 %%%% !
M1110 4444 %%%% 'AO[3W_)M7[0W_9#?BU_Z@/B"O\6&O]I[]I[_ )-J_:&_
M[(;\6O\ U ?$%?XL-?HG W\+,?\ KYAO_2:Q^3>)?\?*/^O6,_\ 2\.%%%%?
M>'Y@%%%% !1110 4444 %%%% '[N?\$'/^"3NH_\%)OVEX_$GQ'TJ^@_9/\
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M8C&SE4QV*3<G"MB)45.5*C242BBBOVT_+@HHHH **** "BBB@ HHHH ****
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M7_@)9?\ R=1_PPU^UO\ ]$'\=?\ @)9?_)U'_$+/$[_HW/'G_B(<0?\ SO\
M-?>'^OO O_1:<)_^)'D__P V'RC17U=_PPU^UO\ ]$'\=?\ @)9?_)U'_##7
M[6__ $0?QU_X"67_ ,G4?\0L\3O^C<\>?^(AQ!_\[_-?>'^OO O_ $6G"?\
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MI_;6_P"BT?\ F.?A-_\ ,)1_P\I_;6_Z+1_YCGX3?_,)1_Q4)\&/^B8\3_\
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MY?!G_LJ_P[_]2_1Z_P '.%?^2GX<_P"Q]D__ *L,.?ZU9_\ \B+.O^Q3F/\
MZAUC^TFBBBO^EH_P]"BBB@ HHHH **** "BBB@ KRCX\_P#)#?C-_P!DH^(G
M_J(:Q7J]>4?'G_DAOQF_[)1\1/\ U$-8KPN*/^29XB_[$6;_ /JOQ!Z_#_\
MR/LD_P"QOEO_ *FT3^+:BBBO^:0_W!/ZU?\ @GQ_R9Q\#O\ L!:]_P"IGXDK
M[+KXT_X)\?\ )G'P._[ 6O?^IGXDK[+K_HS\'_\ DTOA=_V;K@G_ -9K+#_%
MOQ(_Y.)Q[_V6G%/_ *O,<%%%%?HI\6%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?SL?\%C?^2Y?##_LE$?\ ZE_B6OZ)Z_G8_P""QO\
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MO&W_ *'/AU_X?<^_^A8/^)P/"[_H6\:?^&K*?_G_ /U9^5_Y9**_J;_X=?\
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M45K_ !<SBDM6U]ZT445_JR?Y^A1110 4444 %%%% !1110 4444 >&_M/?\
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M4 ?S/?\ !6[_ ).GT_\ [)1X1_\ 3SXKK\P*_3__ (*W?\G3Z?\ ]DH\(_\
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M **** "BBB@ K^=C_@L;_P ER^&'_9*(_P#U+_$M?T3U_.Q_P6-_Y+E\,/\
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M,\91E47>E2E[:JOG3IS/]%6BBBOQ _I$**** "BBB@ HHHH *_F*_P"#C?\
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ME&.K8'%+WZ4KPFD^2M2E=TZU._V)QUMO&2E"5I1DE_H+_P#!L?\ \%>!\<O
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MG_LU2;UQ.%@DE%M_%6PZLG]J='EG:3A5D?J+1117QI^A!1110 4444 %%%%
M!1110 4444 %%%% !1110!_#YXH_Y&;Q%_V'=7_].%Q6%6[XH_Y&;Q%_V'=7
M_P#3A<5A5_S(X[_?<9_V%8C_ -/3/]T<+_NV'_Z\4?\ TW$_IA_X)(_\FL:A
M_P!E7\7?^F;PI7Z?U^8'_!)'_DUC4/\ LJ_B[_TS>%*_3^O^@+Z-_P#R8CPJ
M_P"R-RG_ --,_P @/&W_ ).UQ_\ ]E)C_P#TJ(4445^V'Y:%%%% !1110 44
M44 %%%% !1110 4444 ?S/?\%;O^3I]/_P"R4>$?_3SXKK\P*_3_ /X*W?\
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M_P!//A2OZ8:_F>_X)(_\G3ZA_P!DH\7?^GGPI7],-?Z=_0-_Y,1'_LLN(O\
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M$X?^QLF:ERU/[4S52P]*K1=U^]P.'^LYDE?6."EOL_V1HHHK_H"/\?PHHHH
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M=W]6?E<_XE<\9?\ HG\!_P"'_)?_ )M/Z"J*_GU_X?*_$S_HC/@7_P '^O\
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MG_[+OAW_ -6-$_T!\9/^35>(/_9)YU_ZAU3^GZBBBO\ H5/\<0HHHH ****
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MU:KZPPV94*%&DM+3S*;UOI^FU%%%?ZWG^=I_%?\ $[_@\ _X5S\2?B%\/?\
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MA<-1C@<XC*KB,1@,11HTU*>71@G.I.,4Y2C%-WDTKL_;BBBBO]QS_*H****
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M-!/I?]_*44_Y6U\-U^Z-%%%?DY^YA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '^*_\ M-_\G)?M"?\ 9</B
MQ_ZGNOUX?7VS^TE^S;^T5>_M%?'R\L_@'\:;NSN_C3\4[FUNK;X6>.9[:YMI
M_'.NRP7%O/%H3Q3031.DD4L;-')&RNC,K FQ^S)^PM^T!\:OVCO@)\(-:^!O
MQBT70OB?\8_AKX#U_6M3^&_C72--T70/%7C#1]%US6=1U2ZTFSM].L=*TF\O
M-0O+V6ZMUMK>VDF\Z,H&'[M#$4(8>,Y5::C"C&4GSQT48)O2_1(_F2>$Q-7%
M3IPH57*IB)0C^[G9RG4Y8Z\NS<EKYG^H_P#\$E?@>G[.?_!-3]BOX3FQ_LW4
M-+^ ?@OQ5XCT\PFW>R\9_%"UD^*7CBUEC8[O/A\8>,]<CN)&"M-.LDS1QF0H
MOZ(5!:VMM8VUO965O!:6=I!#:VEI:PQV]M:VUO&L4%O;P1*D4$$$2)%##$BQ
MQQJJ(JJH GK\.KU95ZU:O/XJU6I5E_BJ3<W^+9_2F&H0PN&P^&A\&'H4J$-+
M>Y2IQIQTZ:16@4445D;A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>kymr-20251104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-11-03T17:37:50.4373+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.kymeratx.com/20251104" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:kymr="http://www.kymeratx.com/20251104" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="kymr-20251104.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KYMERA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001815442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2992166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 North Beacon Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">285-5300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KYMR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kymr-20251104.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="kymr-20251104.htm">kymr-20251104.htm</File>
    <File>kymr-20251104.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kymr-20251104.htm": {
   "nsprefix": "kymr",
   "nsuri": "http://www.kymeratx.com/20251104",
   "dts": {
    "inline": {
     "local": [
      "kymr-20251104.htm"
     ]
    },
    "schema": {
     "local": [
      "kymr-20251104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kymr-20251104.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kymr-20251104.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.kymeratx.com/20251104/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-25-263540-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-263540-xbrl.zip
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M@8NG36SXQ 58[ARI4R9,@*2,!->_C3U-]V 0@T846NQ/#&)OX54/5:AL>KI
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MS$:RPC']Q%HF$&E?AV*A@:9$V"<%"73AU_OOSC@VSU(%$,:]<1H7R1*L/X"
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MHYWH]=GT&ZJ<@+]=:X>_S!A>_J2G?H<SNI#XM<[P2OAKH:?_ U!+ P04
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M'^R4A]9"Z+?M0><'R%FO8<$UQV0WD2>^? #^51&:IV=-]@X'DA'Z2(W.876
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M'%4?1S6^>2HCP])LKA+=9']@@H.X$HD/3,=#?[<_8Y<J"_/T$+((HGPW^9/
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M/_[C]:M9.@]__/]02P$"% ,4    " !+.61;@"L[F'@4  "_WP  $0
M        @ $     :WEM<BTR,#(U,3$P-"YH=&U02P$"% ,4    " !+.61;
MK<%$:+@)  !\>0  $0              @ &G%   :WEM<BTR,#(U,3$P-"YX
M<V102P$"% ,4    " !+.61;HR:S)LHJ  "K6@( #P              @ &.
H'@  :WEM<BUE>#DY7S$N:'1M4$L%!@     #  , NP   (5)      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>kymr-20251104_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kymr-20251104.xsd" xlink:type="simple"/>
    <context id="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001815442</identifier>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_aef45e2a-50cd-4f68-9bf7-abf7952e0f93">0001815442</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_28af480e-a392-4669-82b9-9f85c68bceab">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_1b1edc0c-7daf-4641-ae9d-c55b1a68e7b6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_0edf0e27-610e-47c8-ae23-28cd2615c8ce">2025-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_8c07addc-002f-4410-8795-d7c4bdd47f79">KYMERA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_c537a833-31bd-45d6-8823-c3dfa293ae0e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_a3f01367-6d5e-492f-ba1e-817b06ece33b">001-39460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_aa0572d3-eb04-4dc0-9cef-fc4219ed78d8">81-2992166</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_2c43e389-5088-4ea9-b324-4a1c7daf80f1">500 North Beacon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_bcd5fa23-a53a-479c-96cd-e0eeae18f502">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_5e58ef04-7730-4c76-b0d0-60af5cfcdd8d">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_4c1f0bdf-d41d-4238-922a-86f6525fa887">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_d22abd71-088f-43b1-8198-0f38053c0da0">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_35db133c-9c79-435c-82c0-c2abe28d085e">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_1f12f646-c977-47f5-936f-94aea6acd63b">285-5300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_b852d8b8-b166-485f-8937-4f12e0744f4c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_6e4425d4-428e-46f4-9ec0-64c26a61a9bf">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_510d22af-e063-47c9-80cc-a91ebdf25d62">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_8a429b05-6020-4a08-b519-9be2da0988a1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_4944987b-aff5-4920-bb05-321248201262">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_04cdf130-c039-45f8-96c8-63edd4dd1001">KYMR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_449f45c0-f0d5-4781-bf2e-c36cabd5e357">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_96c10396-71dd-4b2e-a08b-ae8dcca1e91b"
      id="F_50110962-ddae-4295-95dd-758c85015a5b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
